ALLMedicine™ Brain Cancer Center

Mar 14th, 2023 - Beyond its use as an antiepileptic drug, over time valproate has been increasingly used for several other therapeutic applications. Among these, the antineoplastic effects of valproate have been assessed in several in vitro and in vivo preclinical...

Mar 12th, 2023 - Magnetic hyperthermia therapy (MHT) is a highly localized form of hyperthermia therapy (HT) that has been effective in treating various forms of cancer. Many clinical and preclinical studies have applied MHT to treat aggressive forms of brain canc...

Mar 9th, 2023 - To prepare the brain cancer specific T cells (GD2-C7R T cells), research staff will take some blood from the patient. We will grow the GD2.C7R T cells by infecting the T cells with a retroviral vector (a special virus that can carry a new gene int...

Mar 8th, 2023 - The composition of the tumor immune microenvironment (TIME) is considered a key determinant of patients' response to immunotherapy. The mechanisms underlying TIME formation and development over time are poorly understood. Glioblastoma (GBM) is a l...

Mar 8th, 2023 - PRIMARY OBJECTIVES: I. Assess the correlation between multiparametric magnetic resonance imaging (mpMRI) radiomics and dynamic 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) PET kinetic analysis parameters. II. Explore the different pat...

Nov 10th, 2020 - To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-Chi...

Mar 9th, 2023 - To prepare the brain cancer specific T cells (GD2-C7R T cells), research staff will take some blood from the patient. We will grow the GD2.C7R T cells by infecting the T cells with a retroviral vector (a special virus that can carry a new gene int...

Mar 8th, 2023 - PRIMARY OBJECTIVES: I. Assess the correlation between multiparametric magnetic resonance imaging (mpMRI) radiomics and dynamic 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) PET kinetic analysis parameters. II. Explore the different pat...

Mar 8th, 2023 - PRIMARY OBJECTIVES: I. Determine the concentration and variability in concentration of navtemadlin (AMG 232 [KRT 232]) in brain and brain-associated tissue in patients with recurrent glioblastoma (GBM). (Part 1) II. Determine the maximum tolerated...

Mar 6th, 2023 - Glioblastoma (GBM) is the most common primary brain cancer in adults. Surgery, chemoradiotherapy (temozolomide TMZ) and then adjuvant TMZ is the standard treatment. But, most patients relapse in a median time of 8-9 months; the median overall surv...

Mar 3rd, 2023 - Glioblastoma is the most aggressive and most common type of primary brain cancer. Standard treatment at diagnosis is surgery followed by high dose radiation therapy and chemotherapy. Despite initial treatment nearly all patients will experience re...

Dec 9th, 2022 - There has been an escalating risk of brain cancer associated with increasing radiation dose to the brain from CT examinations, a cohort study of more than 650,000 children and young adults indicated. Researchers observed a significant dose-respons...

Dec 8th, 2022 - Children and young adults who are exposed to a single CT scan of the head or neck before age 22 years are at significantly increased risk of developing a brain tumor, particularly glioma, after at least 5 years, according to results of the large E...

Dec 6th, 2022 - An investigational vaccine has significantly extended survival in patients with newly diagnosed as well as recurrent glioblastoma, according to new findings from a phase 3 trial (NCT00045968).   "Immunotherapy is a very promising approach for trea...

Nov 28th, 2022 - "Have you considered tissue donation?" These "five simple words" could have profound impact for pediatric brain cancer research — and for children with brain cancer and their families, according to pediatric neuro-oncologist Vijay Ramaswamy, MD, P...

Nov 1st, 2022 - Fam-trastuzumab deruxtecan-nxki (Enhertu) induced meaningful antitumor activity in patients with HER2-positive, HER2-low, or HER2-negative metastatic breast cancer who presented with brain metastases at baseline, according to data from the phase 2...